Apo2L/TRAIL: Phase Ib start

This quarter, the partners plan to begin an open-label, dose-escalation, U.S. Phase Ib trial to evaluate IV dulanermin in combination with FOLFOX chemotherapy and Avastin bevacizumab in 23 previously...